Mission Pharmacal hitches onto TriLogic's delivery tech

TriLogic Pharma has found a new partner for its drug-delivery technology. Mission Pharmacal plans to use TriLogic's delivery tech to develop women's healthcare products, under a deal that gives San Antonio-based Mission a license to the platform for its programs. Financial details of the agreement were not disclosed.

Montgomery, AL-based TriLogic says that drug-delivery platform, TRI-726, can release many active ingredients over a matter of hours or days, using a liquid-to-gel formulation and materials that can be safely absorbed in the body. The company markets animal health products such as anti-bacterial toothpaste and surgical gels used in orthopedic procedures on animals, according to the firm's website.

"Mission Pharmacal's growth over the last 60 years has been the result of good relationships with other innovative pharmaceutical companies. We look forward to working with TriLogic and its new technology," Terry Herring, president of Mission Pharmacal's commercial operations, said in statement.

- here's the release
- see the San Antonio Business Journal's piece

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.